Balise, R. R., Hu, M.-C., Calderon, A. R., Odom, G. J., Brandt, L., Luo, S. X., & Feaster, D. J. (2024). Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder. PLOS ONE, 19(11), e0312695. https://doi.org/10.1371/journal.pone.0312695

Presskreischer, R., Mojtabai, R., Mauro, C., Zhang, Z., Wall, M., & Olfson, M. (2025). Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020. Journal of Substance Use and Addiction Treatment, 168, 209568. https://doi.org/10.1016/j.josat.2024.209568

Ross, R. K., Inose, S., Shulman, M., Nunes, E. V., Zalla, L. C., Burlew, A. K., & Rudolph, K. E. (2024). Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open, 7(10), e2436612. https://doi.org/10.1001/jamanetworkopen.2024.36612

Williams, A. R., Mauro, C. M., Chiodo, L., Huber, B., Cruz, A., Crystal, S., Samples, H., Nowels, M., Wilson, A., Friedmann, P. D., Remien, R. H., & Olfson, M. (2024). Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug and Alcohol Dependence, 263, 112389. https://doi.org/10.1016/j.drugalcdep.2024.112389

Williams, A. R., Mauro, C. M., Huber, B., Chiodo, L., Crystal, S., Samples, H., & Olfson, M. (2024). Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement. American Journal of Psychiatry, 181(5), 457–459. https://doi.org/10.1176/appi.ajp.20230808